EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Economic Profit
Net Operating Profit after Taxes (NOPAT)
Cash Operating Taxes
Invested Capital
Cost of Capital
Economic Spread Ratio
Economic Profit Margin

Eli Lilly & Co., economic profit calculation

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net operating profit after taxes (NOPAT)¹	8,466,038)	3,090,452)	4,320,468)	5,040,358)	6,357,340)
Cost of capital²	8.45%	8.47%	8.37%	8.15%	8.07%
Invested capital³	35,800,600)	29,384,700)	24,302,500)	26,139,800)	24,557,100)

Economic profit⁴	5,439,775)	602,563)	2,285,982)	2,911,131)	4,374,701)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ NOPAT. See details »

² Cost of capital. See details »

³ Invested capital. See details »

⁴ 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= 8,466,038 – 8.45% × 35,800,600 = 5,439,775

Download chart

Item	Description	The company
Economic profit	Economic profit is a measure of corporate performance computed by taking the spread between the return on invested capital and the cost of capital, and multiplying by the invested capital.	Eli Lilly & Co. economic profit decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Eli Lilly & Co., NOPAT calculation

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	10,590,000)	5,240,400)	6,244,800)	5,581,700)	6,193,700)
Deferred income tax expense (benefit)¹	(2,683,100)	(2,341,000)	(2,185,200)	(802,300)	(134,500)
Increase (decrease) in allowances²	100)	(1,200)	(6,500)	(3,400)	3,500)
Increase (decrease) in LIFO reserve³	39,500)	(93,500)	25,300)	600)	16,400)
Increase (decrease) in equity equivalents⁴	(2,643,500)	(2,435,700)	(2,166,400)	(805,100)	(114,600)
Interest expense	780,600)	485,900)	331,600)	339,800)	359,600)
Interest expense, operating lease liability⁵	52,744)	48,611)	26,215)	20,571)	21,902)
Adjusted interest expense	833,344)	534,511)	357,815)	360,371)	381,502)
Tax benefit of interest expense⁶	(175,002)	(112,247)	(75,141)	(75,678)	(80,115)
Adjusted interest expense, after taxes⁷	658,341)	422,264)	282,674)	284,693)	301,387)
(Gain) loss on marketable securities	(500)	800)	11,400)	(1,100)	3,700)
Interest income	(175,200)	(173,600)	(62,800)	(25,400)	(33,000)
Investment income, before taxes	(175,700)	(172,800)	(51,400)	(26,500)	(29,300)
Tax expense (benefit) of investment income⁸	36,897)	36,288)	10,794)	5,565)	6,153)
Investment income, after taxes⁹	(138,803)	(136,512)	(40,606)	(20,935)	(23,147)
Net operating profit after taxes (NOPAT)	8,466,038)	3,090,452)	4,320,468)	5,040,358)	6,357,340)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Elimination of deferred tax expense. See details »

² Addition of increase (decrease) in allowances.

³ Addition of increase (decrease) in LIFO reserve. See details »

⁴ Addition of increase (decrease) in equity equivalents to net income.

⁵ 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= 1,146,600 × 4.60% = 52,744

⁶ 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= 833,344 × 21.00% = 175,002

⁷ Addition of after taxes interest expense to net income.

⁸ 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= 175,700 × 21.00% = 36,897

⁹ Elimination of after taxes investment income.

Download chart

Item	Description	The company
NOPAT	Net operating profit after taxes is income from operations, but after removement of taxes calculated on cash basis that are relevant to operating income.	Eli Lilly & Co. NOPAT decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Eli Lilly & Co., cash operating taxes calculation

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Income taxes	2,090,400)	1,314,200)	561,600)	573,800)	1,036,200)
Less: Deferred income tax expense (benefit)	(2,683,100)	(2,341,000)	(2,185,200)	(802,300)	(134,500)
Add: Tax savings from interest expense	175,002)	112,247)	75,141)	75,678)	80,115)
Less: Tax imposed on investment income	36,897)	36,288)	10,794)	5,565)	6,153)
Cash operating taxes	4,911,605)	3,731,159)	2,811,147)	1,446,213)	1,244,662)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
Cash operating taxes	Cash operating taxes are estimated by adjusting income tax expense for changes in deferred taxes and tax benefit from the interest deduction.	Eli Lilly & Co. cash operating taxes increased from 2022 to 2023 and from 2023 to 2024.

Eli Lilly & Co., invested capital calculation (financing approach)

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term borrowings and current maturities of long-term debt	5,117,100)	6,904,500)	1,501,100)	1,538,300)	8,700)
Long-term debt, excluding current maturities	28,527,100)	18,320,800)	14,737,500)	15,346,400)	16,586,600)
Operating lease liability¹	1,146,600)	1,104,800)	728,200)	685,700)	663,700)
Total reported debt & leases	34,790,800)	26,330,100)	16,966,800)	17,570,400)	17,259,000)
Total Eli Lilly and Company shareholders’ equity	14,192,100)	10,771,900)	10,649,800)	8,979,200)	5,641,600)
Net deferred tax (assets) liabilities²	(7,926,700)	(5,373,400)	(2,705,700)	(755,900)	(730,500)
Allowances³	14,900)	14,800)	16,000)	22,500)	25,900)
LIFO reserve⁴	(62,900)	(102,400)	(8,900)	(34,200)	(34,800)
Equity equivalents⁵	(7,974,700)	(5,461,000)	(2,698,600)	(767,600)	(739,400)
Accumulated other comprehensive (income) loss, net of tax⁶	4,321,900)	4,327,000)	3,844,600)	4,343,100)	6,496,400)
Noncontrolling interests	79,500)	91,800)	125,600)	175,600)	183,600)
Adjusted total Eli Lilly and Company shareholders’ equity	10,618,800)	9,729,700)	11,921,400)	12,730,300)	11,582,200)
Construction in progress⁷	(8,244,800)	(5,084,100)	(2,798,600)	(2,177,800)	(2,138,800)
Investments⁸	(1,364,200)	(1,591,000)	(1,787,100)	(1,983,100)	(2,145,300)
Invested capital	35,800,600)	29,384,700)	24,302,500)	26,139,800)	24,557,100)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Addition of capitalized operating leases.

² Elimination of deferred taxes from assets and liabilities. See details »

³ Addition of allowance for doubtful accounts receivable.

⁴ Addition of LIFO reserve. See details »

⁵ Addition of equity equivalents to total Eli Lilly and Company shareholders’ equity.

⁶ Removal of accumulated other comprehensive income.

⁷ Subtraction of construction in progress.

⁸ Subtraction of investments.

Download chart

Item	Description	The company
Invested capital	Capital is an approximation of the economic book value of all cash invested in going-concern business activities.	Eli Lilly & Co. invested capital increased from 2022 to 2023 and from 2023 to 2024.

Eli Lilly & Co., cost of capital calculations

Dec 31, 2024

	Capital (fair value)¹	Weights					Cost of capital
Equity²	822,110,798)	822,110,798)	÷	853,825,798)	=	0.96	0.96	×	8.66%	=	8.34%
Debt³	30,568,400)	30,568,400)	÷	853,825,798)	=	0.04	0.04	×	3.87% × (1 – 21.00%)	=	0.11%
Operating lease liability⁴	1,146,600)	1,146,600)	÷	853,825,798)	=	0.00	0.00	×	4.60% × (1 – 21.00%)	=	0.00%
Total:	853,825,798)					1.00					8.45%

Based on: 10-K (reporting date: 2024-12-31).

¹ US$ in thousands

² Equity. See details »

³ Debt. See details »

⁴ Operating lease liability. See details »

Dec 31, 2023

	Capital (fair value)¹	Weights					Cost of capital
Equity²	708,737,166)	708,737,166)	÷	733,230,066)	=	0.97	0.97	×	8.66%	=	8.37%
Debt³	23,388,100)	23,388,100)	÷	733,230,066)	=	0.03	0.03	×	3.58% × (1 – 21.00%)	=	0.09%
Operating lease liability⁴	1,104,800)	1,104,800)	÷	733,230,066)	=	0.00	0.00	×	4.40% × (1 – 21.00%)	=	0.01%
Total:	733,230,066)					1.00					8.47%

Based on: 10-K (reporting date: 2023-12-31).

¹ US$ in thousands

² Equity. See details »

³ Debt. See details »

⁴ Operating lease liability. See details »

Dec 31, 2022

	Capital (fair value)¹	Weights					Cost of capital
Equity²	312,713,944)	312,713,944)	÷	327,263,444)	=	0.96	0.96	×	8.66%	=	8.28%
Debt³	13,821,300)	13,821,300)	÷	327,263,444)	=	0.04	0.04	×	2.69% × (1 – 21.00%)	=	0.09%
Operating lease liability⁴	728,200)	728,200)	÷	327,263,444)	=	0.00	0.00	×	3.60% × (1 – 21.00%)	=	0.01%
Total:	327,263,444)					1.00					8.37%

Based on: 10-K (reporting date: 2022-12-31).

¹ US$ in thousands

² Equity. See details »

³ Debt. See details »

⁴ Operating lease liability. See details »

Dec 31, 2021

	Capital (fair value)¹	Weights					Cost of capital
Equity²	226,953,844)	226,953,844)	÷	245,797,244)	=	0.92	0.92	×	8.66%	=	8.00%
Debt³	18,157,700)	18,157,700)	÷	245,797,244)	=	0.07	0.07	×	2.44% × (1 – 21.00%)	=	0.14%
Operating lease liability⁴	685,700)	685,700)	÷	245,797,244)	=	0.00	0.00	×	3.00% × (1 – 21.00%)	=	0.01%
Total:	245,797,244)					1.00					8.15%

Based on: 10-K (reporting date: 2021-12-31).

¹ US$ in thousands

² Equity. See details »

³ Debt. See details »

⁴ Operating lease liability. See details »

Dec 31, 2020

	Capital (fair value)¹	Weights					Cost of capital
Equity²	197,876,569)	197,876,569)	÷	217,579,169)	=	0.91	0.91	×	8.66%	=	7.88%
Debt³	19,038,900)	19,038,900)	÷	217,579,169)	=	0.09	0.09	×	2.74% × (1 – 21.00%)	=	0.19%
Operating lease liability⁴	663,700)	663,700)	÷	217,579,169)	=	0.00	0.00	×	3.30% × (1 – 21.00%)	=	0.01%
Total:	217,579,169)					1.00					8.07%

Based on: 10-K (reporting date: 2020-12-31).

¹ US$ in thousands

² Equity. See details »

³ Debt. See details »

⁴ Operating lease liability. See details »

Eli Lilly & Co., economic spread ratio calculation, comparison to benchmarks

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit¹	5,439,775)	602,563)	2,285,982)	2,911,131)	4,374,701)
Invested capital²	35,800,600)	29,384,700)	24,302,500)	26,139,800)	24,557,100)
Performance Ratio
Economic spread ratio³	15.19%	2.05%	9.41%	11.14%	17.81%
Benchmarks
Economic Spread Ratio, Competitors⁴
AbbVie Inc.	-2.77%	-4.48%	4.95%	4.38%	-3.42%
Amgen Inc.	0.09%	2.89%	7.48%	7.46%	11.78%
Bristol-Myers Squibb Co.	—	1.79%	-0.94%	1.33%	-14.22%
Danaher Corp.	—	-8.28%	-3.32%	-2.64%	-4.03%
Gilead Sciences Inc.	—	5.82%	2.31%	8.86%	-4.20%
Johnson & Johnson	1.64%	-0.21%	5.06%	10.12%	4.92%
Merck & Co. Inc.	—	-8.77%	11.41%	11.57%	4.41%
Pfizer Inc.	—	-9.25%	18.24%	11.40%	-3.28%
Regeneron Pharmaceuticals Inc.	21.10%	17.94%	23.29%	66.98%	38.48%
Thermo Fisher Scientific Inc.	—	-5.12%	-3.35%	-1.51%	-0.52%
Vertex Pharmaceuticals Inc.	—	11.77%	14.52%	15.73%	29.00%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Economic profit. See details »

² Invested capital. See details »

³ 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × 5,439,775 ÷ 35,800,600 = 15.19%

⁴ Click competitor name to see calculations.

Download chart

Performance ratio	Description	The company
Economic spread ratio	The ratio of economic profit to invested capital, also equal to the difference between return on invested capital (ROIC) and cost of capital.	Eli Lilly & Co. economic spread ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Eli Lilly & Co., economic profit margin calculation, comparison to benchmarks

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selected Financial Data (US$ in thousands)
Economic profit¹	5,439,775)	602,563)	2,285,982)	2,911,131)	4,374,701)
Revenue	45,042,700)	34,124,100)	28,541,400)	28,318,400)	24,539,800)
Performance Ratio
Economic profit margin²	12.08%	1.77%	8.01%	10.28%	17.83%
Benchmarks
Economic Profit Margin, Competitors³
AbbVie Inc.	-3.40%	-5.63%	7.01%	7.47%	-7.74%
Amgen Inc.	0.18%	7.52%	11.98%	12.35%	18.85%
Bristol-Myers Squibb Co.	—	2.68%	-1.46%	2.31%	-30.15%
Danaher Corp.	—	-27.19%	-8.26%	-6.61%	-11.82%
Gilead Sciences Inc.	—	9.90%	3.89%	15.67%	-8.67%
Johnson & Johnson	1.97%	-0.24%	6.06%	10.58%	5.85%
Merck & Co. Inc.	—	-10.21%	14.23%	16.80%	5.25%
Pfizer Inc.	—	-24.49%	20.13%	12.30%	-8.14%
Regeneron Pharmaceuticals Inc.	18.50%	16.36%	23.45%	45.30%	37.50%
Thermo Fisher Scientific Inc.	—	-10.23%	-6.18%	-3.08%	-0.99%
Vertex Pharmaceuticals Inc.	—	15.80%	21.42%	19.49%	38.06%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Economic profit. See details »

² 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × 5,439,775 ÷ 45,042,700 = 12.08%

³ Click competitor name to see calculations.

Download chart

Performance ratio	Description	The company
Economic profit margin	The ratio of economic profit to sales. It is the company profit margin covering income efficiency and asset management. Economic profit margin is not biased in favor of capital-intensive business models, because any added capital is a cost to the economic profit margin.	Eli Lilly & Co. economic profit margin deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Eli Lilly & Co. (NYSE:LLY)

Economic Value Added (EVA)

Economic Profit

Net Operating Profit after Taxes (NOPAT)

Cash Operating Taxes

Invested Capital

Cost of Capital

Economic Spread Ratio

Economic Profit Margin